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Dependent Manner
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Abstract
Although human immunodeficiency virus (HIV) types 1 and 2 are closely related lentiviruses
with similar replication cycles, HIV-2 infection is associated with slower progression to
AIDS, a higher proportion of long term non-progressors, and lower rates of transmission
than HIV-1, likely as a consequence of a lower viral load during HIV-2 infection. A mechanis-
tic explanation for the differential viral load remains unclear but knowledge of differences in
particle production between HIV-1 and HIV-2 may help to shed light on this issue. In con-
trast to HIV-1, little is known about the assembly of HIV-2 particles, and the trafficking of
HIV-2 Gag, the structural component of the virus, within cells. We have established that
HIV-2 Gag accumulates in intracellular CD63 positive compartments, from which it may be
delivered or recycled to the cell surface, or degraded. HIV-2 particle release was dependent
on the adaptor protein complex AP-3 and the newly identified AP-5 complex, but much less
so on AP-1. In contrast, HIV-1 particle release required AP-1 and AP-3, but not AP-5. AP-2,
an essential component of clathrin-mediated endocytosis, which was previously shown to
be inhibitory to HIV-1 particle release, had no effect on HIV-2. The differential requirement
for adaptor protein complexes confirmed that HIV-1 and HIV-2 Gag have distinct cellular
trafficking pathways, and that HIV-2 particles may be more susceptible to degradation prior
to release.
Introduction
Human immunodeficiency virus (HIV) types 1 and 2 are closely related lentiviruses that are
the causative agents of Acquired Immune Deficiency Syndrome (AIDS). If left untreated, the
majority of patients infected with HIV-1 will develop AIDS within 8–10 years of infection,
whereas only a minority of patients infected with HIV-2 will develop AIDS, and over a longer
timespan [1, 2]. HIV-2 is also less transmissible than HIV-1 [3], and has not spread widely
fromWest Africa. These differences are likely a consequence of the different levels of virus
found in patients during the clinically asymptomatic phase of HIV-1 or -2 infection [4]. Cohort
studies have shown that circulating viral loads of HIV-2 are lower than HIV-1 during infection,
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despite similar levels of integrated proviral DNA [5], although the reasons for this difference
remain unclear. The replication cycles of the two lentiviruses are similar, but HIV-2 is less
well-studied than HIV-1, leaving potential mechanistic differences yet to be characterized.
Understanding how HIV-1 and HIV-2 differ in the production and release of viral particles
could enable the discovery of new ways to target the more pathogenic HIV-1, and more specific
ways to target HIV-2.
The assembly and budding of lentiviral particles is directed by the Gag polyprotein; expres-
sion of HIV-1 or -2 Gag alone can result in the production of virus-like particles that bud out
of cells [6, 7]. During viral infection, Gag and GagPol polyproteins are synthesized in the cyto-
plasm before assembling into multimeric structures at membranes. The major site of HIV-1
particle assembly in T cells and a number of cell lines such as 293T and HeLa is the plasma
membrane [8, 9], in cholesterol and tetraspanin-enriched microdomains [10]. However the
route by which HIV-1 Gag arrives at the plasma membrane is less clear; trafficking via endoso-
mal compartments to the plasma membrane has been shown [11], as has direct trafficking to
the plasma membrane followed by internalization into endosomes [9]. In macrophages, HIV-1
assembles at intracellular membranes; originally described as late endosomes or multivesicular
bodies [12, 13], these virion containing compartments (VCCs) have been shown to be non-
acidic [14], tetraspanin-enriched [15], and linked by very narrow channels to the plasma mem-
brane [14].
The trafficking of HIV-1 Gag from its site of synthesis to its site(s) of assembly may be a
passive, diffusion-limited process, or an active process mediated, for example, by cellular vesic-
ular transport pathways. Supporting this, the clathrin adaptor proteins AP-1, -2 and -3 have
been shown to interact with HIV-1 Gag and affect HIV-1 particle release [16–18]. Clathrin
adaptor proteins are involved in the vesicular trafficking of proteins between the trans-Golgi
network, endosomes, lysosomes and plasma membrane. The adaptor proteins recognize motifs
on membrane-bound cargo proteins and promote the formation of clathrin coated cargo vesi-
cles. AP-2 is found at the plasma membrane and is involved in clathrin-mediated endocytosis,
AP-1 is found on Golgi and endosomal membranes, and AP-3 on endosomal and lysosomal
membranes [19]. A new adaptor protein (AP-5) has recently been discovered [20] and is found
on late endosomal/lysosomal membranes [21], although much less is known about the func-
tion of this protein.
In this study we investigated the distribution of HIV-2 Gag in HeLa and 293T cells and the
role of AP-1, -2, -3 and -5 in HIV-2 Gag trafficking. We found that HIV-2 Gag traffics to intra-
cellular CD63 positive compartments. HIV-2 particle release was dependent on AP-3, which
was recruited to Gag-containing compartments, and AP-5, but much less so on AP-1. In con-
trast, HIV-1 particle release required AP-1 and AP-3, as previously shown, but not AP-5. AP-
2, which has previously been shown to inhibit HIV-1 particle release, had no effect on HIV-2
release.
Materials and Methods
Plasmids and siRNAs
Proviral plasmids used in this study were pSVC21ΔBgl (HIV-1 HxB2 strain with nucleotides
6587–7167 deleted), pSVR (HIV-2 ROD strain) and pSVRΔNB [22]. pSVR is a full length
HIV-2 molecular clone, pSVC21ΔBgl and pSVRΔNB have deletions in the env gene but con-
tain a functional Rev response element. These plasmids were a gift from Professor Andrew
Lever. Custom siRNAs based on published siRNA sequences were ordered from Life Technolo-
gies: AP-1γ GCGCCUGUACAAAGCAAUU [16]; AP-2μ GUGGAUGCCUUUCGGGUCA
[23]; AP-3δ CCCUGUCCUUCAUUGCCAA [16]. AP-5μON-TARGETplus AP5M1 J-
HIV-2 Gag Trafficking
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015523-09 [20] was ordered from Dharmacon. Silencer negative control #2 was also used (Life
Technologies). All siRNAs were used at 10 nM final concentration except AP-5μ siRNA which
was used at 25nM, as previously published [20].
Tissue culture and transfections
HeLa (ATCC: CCL-2) and human embryonic kidney 293T (ATCC: CRL-11268) cells were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum.
Transfections were carried out using Lipofectamine 2000 (Invitrogen) in 12 well plates using
0.5 μg / well proviral plasmid, according to the manufacturer’s instructions. For western blot-
ting, cells were harvested 42 hours post-transfection using passive lysis buffer (Promega). Total
protein content of each cell sample was measured using the BCA protein assay kit (Thermo Sci-
entific). Cell supernatants were filtered through a 0.2 μmmembrane and virions precipitated
overnight at 4°C with 0.5 vol 30% PEG-8000 in 0.4 M NaCl. Viral particles were pelleted and
resuspended in PBS. Following SDS polyacrylamide gel electrophoresis and electroblotting to
nitrocellulose, viral Gag proteins were detected using polyclonal antiserum to HIV-1 p24
(ARP432, Dr G Reid) or polyclonal antiserum to SIV p27 (ARP414, Dr M Page), from Pro-
gramme EVA, Centre for AIDS Reagents, NIBSC. Western blots were analyzed using Image J.
Confocal immunofluorescence microscopy
Cells were plated and transfected with siRNAs and/or proviral plasmids on cover slips in 12
well plates. 42 hours post-transfection, cells were fixed in PBS / 10% formaldehyde for 10 min-
utes and permeabilized in PBS / 0.5% NP40 for 10 minutes. Cells were then blocked in PBS /
1% BSA for 1 hour and stained using rabbit antiserum to HIV-1 p24 (ARP432) or sheep antise-
rum to SIV p27 (ARP414), followed by donkey Alexa Fluor 594-tagged anti-rabbit or anti-
sheep IgG (Invitrogen). Other antibodies used were mouse monoclonal antibodies against
CD63 (Abcam ab8219), CD81 (Santa Cruz sc23962), AP-3δ (BD Biosciences 611328) and cla-
thrin heavy chain (X22, a gift from Professor Frances Brodsky). These were then detected with
donkey Alexa Fluor 488-tagged anti-mouse IgG (Invitrogen). Cover slips were mounted onto
standard glass microscope slides using VectaShield (Vector Laboratories) with DAPI and visu-
alized using a 63x oil objective (Leica SP5). Co-localization analysis was carried out using
Image J.
Reverse transcription-quantitative PCR (RT-qPCR)
HeLa cells were harvested 42 hours post-transfection with AP-5 and negative control siRNAs.
RNA was isolated with an RNeasy kit (Qiagen) and cDNA was synthesized using a high capac-
ity RNA-to-cDNA kit (Applied Biosystems). The cDNA was used as a template for real time
PCR with 2x Fast SYBR Green master mix (Applied Biosystems) and the following primers:
AP5f CACCGTGAGATTCTCCAGACG and AP5r TGGCCAGAGTTCTTCACCTCC; gapdhf
TCTCCTCTGACTTCAACAGCGAC and gapdhr CCCTGTTGCTGTAGCCAAATTC. Amplifica-
tion and detection were carried out using an ABI 7000 Sequence Detection System.
Results
HIV-2 Gag localizes to intracellular compartments
HIV-1 Gag has been shown to aggregate and assemble into viral particles at the plasma mem-
brane in T cells, 293T cells and HeLa cells [8, 9], whereas in macrophages intracellular VCCs
have been shown to be the site of assembly [14, 15]. We investigated the cellular distribution of
HIV-1 and -2 Gag using confocal immunofluorescence microscopy of cells transfected with
HIV-2 Gag Trafficking
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proviral plasmids. HIV-1 Gag was observed to display one of three distributions: diffuse in the
cytoplasm (Fig 1A), plasma membrane-associated (Fig 1B), or punctate (Fig 1C), as has been
previously reported [24]. HIV-2 Gag was observed to be punctate (Fig 1D) or plasma mem-
brane-associated (Fig 1E). The different patterns of HIV-1 and HIV-2 Gag distribution were
quantified by assessing several hundred cells from independent experiments. For HIV-1,
Fig 1. HIV-1 and -2 Gag differ in their subcellular distribution. Confocal immunofluorescence microscopy of HeLa
cells transfected with envelope-deleted proviral plasmids. Gag immunofluorescence is shown in red, DAPI staining in
blue. (A-C) HIV-1, (D, E) HIV-2. Scale bars are shown in the bottom right corner of each image. (F) Quantification of Gag
distribution is shown graphically. Several hundred cells from three independent experiments were assessed by two
different people. Cells were scored as having predominantly plasmamembrane (PM), punctate intracellular (punctate),
or diffuse cytoplasmic (diffuse) distribution of Gag. Error bars represent the standard deviation.
doi:10.1371/journal.pone.0158941.g001
HIV-2 Gag Trafficking
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around 65% of cells showed a predominantly diffuse distribution of Gag, 18% punctate and
16% plasma membrane-associated, whereas for HIV-2, no cells had a diffuse distribution,
75% showed a punctate distribution, and 25% of cells had plasma membrane-associated Gag
(Fig 1F).
The predominantly punctate distribution of HIV-2 Gag was observed in both the presence
(Fig 2A) and absence (Fig 1) of HIV-2 Env, indicating that Env does not affect HIV-2 Gag
localization. HIV-2 Gag also had a punctate distribution in 293T cells (Fig 2B), which indicates
that it is not a pattern that is specific to HeLa cells or due to tetherin expression [25]. To inves-
tigate the identity of the intracellular compartment to which HIV-2 Gag is associated, co-
Fig 2. HIV-2 Gag localizes to CD63+/CD81+ compartments. Confocal immunofluorescence microscopy of
HeLa cells (unless stated) transfected with proviral plasmids. Gag immunofluorescence is shown in red, DAPI
staining in blue. (A) full length HIV-2 (expressing Env), (B) HIV-2 in 293T cells. (C) HIV-1, co-staining for Gag
(red) and CD63 (green), (D) HIV-2, co-staining for Gag (red) and CD63 (green), (E) HIV-1, co-staining for Gag
(red) and CD81 (green), (F) HIV-2, co-staining for Gag (red) and CD81 (green). Mean Gag and CD63 or CD81
co-localization (Pearson’s correlation coefficient, Rr) is shown to the right of images C and D or E and F
respectively. Scale bars are shown in the bottom right corner of each image.
doi:10.1371/journal.pone.0158941.g002
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localization studies were carried out with the tetraspanins CD63 (late endosome marker) and
CD81, a plasma membrane protein that has been shown to be present in macrophage VCCs
[15]. HIV-1 Gag did not co-localize with either CD63 (Fig 2C) or CD81 (Fig 2E), with a Pear-
son’s correlation coefficient (Rr) of 0.266 and 0.219 respectively. However, HIV-2 Gag co-
localized strongly with both CD63 (Fig 2D, Rr = 0.623) and CD81 (Fig 2F, Rr = 0.593). Nota-
bly, in cells expressing HIV-2 Gag, CD81 showed a punctate intracellular distribution in addi-
tion to the plasma membrane association seen in cells expressing HIV-1 Gag. This suggests
that either these intracellular compartments are linked via microchannels to the plasma mem-
brane, or that CD81 has been internalized from the cell surface.
The effect of depleting adaptor proteins 1, 2 or 3 shows different
trafficking pathways of HIV-1 and HIV-2 Gag
HIV-1 Gag has previously been reported to interact with the clathrin adaptor proteins AP-1
[16], AP-2 [17] and AP-3 [18]. AP-2 functions at the plasma membrane in clathrin-mediated
endocytosis and has been shown to be inhibitory to HIV-1 particle release [17]. AP-1 and -3,
involved in TGN-endosome and endosome-lysosome trafficking [19], respectively, are
reported to be required for HIV-1 particle release. Furthermore, the distribution of HIV-1 Gag
in cells derived from Hermansky-Pudlak syndrome patients, who lack functional AP-3, was
shown to be different to that in wild type cells [26]. We used siRNA-mediated knock down to
determine whether HIV-2 Gag interacts with the clathrin adaptor proteins in the same way.
We have previously reported that prior siRNA knock down of AP-1 or AP-3 significantly
affects the efficiency with which cells can be transfected with plasmid DNA [27]. Therefore, we
co-transfected HeLa cells with siRNAs for AP-1, -2 or -3 at the same time as HIV-1 or HIV-2
proviral plasmids. Western blotting confirmed the efficient and specific knock down of AP-1γ,
AP-2μ or AP-3δ subunits (Fig 3A–3C) and thus the level of the functional tetrameric com-
plexes. First we tested whether knocking down AP-1, -2 or -3 had an effect on the distribution
of HIV-1 and HIV-2 Gag by confocal immunofluorescence microscopy (Fig 3D and 3E respec-
tively), which was quantified as described above. The presence of AP-2 siRNA or the negative
control siRNA (-ve) had no significant effect on the distribution of HIV-1 Gag (Fig 3D). AP-1
siRNA significantly reduced the percentage of cells with plasma membrane-associated HIV-1
Gag, with corresponding small but insignificant increases in punctate and diffuse Gag. AP-3
siRNA also significantly reduced plasma membrane-associated Gag, with a corresponding
increase in punctate Gag, a result that corroborates that seen with HIV-1 Gag in Hermansky-
Pudlak syndrome cells [26]. For HIV-2 (Fig 3E), as with HIV-1 Gag, the presence of AP-2
or—ve siRNA had no significant effect on the distribution of HIV-2 Gag. AP-1 siRNA reduced
the percentage of cells with plasma membrane-associated HIV-2 Gag and increased the per-
centage with punctate Gag. AP-3 siRNA had a greater effect, almost completely eliminating
plasma membrane-associated Gag (2% of cells), with a corresponding increase in punctate
Gag (98% of cells). These results demonstrate a similar role for AP-1 and AP-3 in allowing
accumulation of HIV-2 Gag at the plasma membrane, and suggest that AP-3 at least may be
required for trafficking of Gag from intracellular compartments to the plasma membrane.
However, the fact that AP siRNA treatment had little effect on the majority of cells with a dif-
fuse distribution of HIV-1 Gag suggests that the major trafficking pathways may be different
for HIV-1 and HIV-2 Gag.
We next tested whether knock down of AP-1, -2 or -3 affected the levels of cell-associated
and virion-associated full-length and processed Gag. During and after assembly of Gag and
GagPol into particles, the viral protease cleaves Gag into its constituent proteins: MA, CA, NC,
p6 (and two spacer peptides), which are then rearranged to produce the mature virion. Western
HIV-2 Gag Trafficking
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Fig 3. siRNA-mediated knockdown of AP-1 or AP-3 reduces plasmamembrane localization and increases punctate
distribution of HIV-2 Gag. (A-C) HeLa cells were harvested 42 hours post-transfection with 10 nM siRNA against AP-1γ, AP-2μ, AP-
3δ, AP-1γ and AP-3δ, or negative control siRNA (-ve), or mock transfected (none). Western blots of cell lysates were probed with
antibodies against AP-1γ (A), AP-2μ (B) and AP-3δ (C). The blots were also probed with an antibody against γ tubulin, as a control. In
(B), the antibody that recognizes AP-2μ also recognizes AP-1μ, which serves as an additional control. Panels separated by a dotted
line represent different parts of the same blot. (D, E) HeLa cells were co-transfected with HIV-1 (D) or HIV-2 (E) proviral plasmids and
no siRNA, siRNAs against AP-1γ, AP-2μ or AP-3δ, or a negative control siRNA (-ve), and observed by confocal immunofluorescence
microscopy. Quantification of the effect of siRNAs on Gag distribution is shown graphically (D and E). For each siRNA treatment, at
least 200 cells were assessed from three independent experiments by two different people. Cells were scored as having
predominantly plasmamembrane (PM), punctate intracellular (punctate), or diffuse cytoplasmic (diffuse) distribution of Gag. Error
bars represent the standard deviation and significant changes from no siRNA treatment are shown with an asterisk (p < 0.05).
doi:10.1371/journal.pone.0158941.g003
HIV-2 Gag Trafficking
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blotting of cell lysates using anti-CA antibodies detects full length Gag (p55 and p57 for HIV-1
and -2 respectively), fully processed CA (p24 and p27 for HIV-1 and -2 respectively), and in
the case of HIV-1 only, an MA-CA intermediate (p41). Western blotting of viral supernatants
detects only fully processed p24 or p27 CA.
For HIV-1 (Fig 4A and 4B), in agreement with previously published data [17], we found
that AP-2 siRNA had no effect on cell-associated Gag, but greatly increased the amount of
virion-associated p24 (CA). AP-1 or AP-3 siRNAs did not reduce the level of cell-associated
p55 Gag, but reduced the level of virion-associated p24 (CA) by around 50%, as has been
Fig 4. siRNA-mediated knockdown of AP-1, -2 and -3 have different effects on HIV-1 and HIV-2 particle
release. HeLa cells were co-transfected with HIV-1 (A, B) or HIV-2 (C, D) proviral plasmids and no siRNA
(none), siRNAs against AP-1γ, AP-2μ or AP-3δ, or a negative control siRNA (-ve). 42 hours post-transfection,
cell lysates and viral supernatants were harvested. Cell-associated (A, C) and virion-associated (B, D) HIV-1
p55 (full length Gag), p41 (MA-CA) and p24 (CA), and HIV-2 p57 (full length Gag) and p27 (CA) were
detected by western blotting (representative blots shown to the right) and quantified using densitometry. Error
bars represent the standard error of the mean from three independent experiments and significant changes
from no siRNA treatment are shown with an asterisk (p < 0.05).
doi:10.1371/journal.pone.0158941.g004
HIV-2 Gag Trafficking
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published previously [16, 18]. We did see a reduction in the relative level of p24 in cells treated
with AP-1 siRNA (Fig 4A), suggesting either that Gag processing was reduced, (perhaps
because less Gag was reaching the plasma membrane to assemble into particles), or that p24
was being degraded. We also treated cells with siRNAs for both AP-1 and AP-3 together. In
this case, a small but significant reduction was seen in the level of cell-associated p55 Gag and
p41 (MA-CA processing intermediate) and a greater reduction in cell-associated p24 (Fig 4A).
There was also an additive effect of AP-1 and AP-3 siRNAs on virion release (Fig 4B), suggest-
ing that AP-1 and AP-3 act on different trafficking pathways rather than the same one,
although there may be some overlap. The results for HIV-2 (Fig 4C and 4D) were different.
Firstly, knock down of AP-2 had no effect on cell- or virion-associated Gag, which shows that
AP-2 is not inhibitory to HIV-2 particle release as it is for HIV-1. This suggests that HIV-2
Gag is not internalized from the plasma membrane by clathrin-mediated endocytosis. Sec-
ondly, AP-1 or AP-3 siRNA treatment reduced cell-associated p57 Gag by 25% and 50%
respectively, with the level of cell-associated p27 (CA) reduced by a similar amount or less
(25% and 35% for AP-1 and AP-3 siRNAs respectively; Fig 4C). This shows that AP-1 and par-
ticularly AP-3 siRNA treatment results in increased degradation of HIV-2 Gag, but also that
HIV-2 Gag processing (and thus particle assembly) is not compromised by AP knock down.
Thirdly, the level of virion-associated p27 was reduced by 25% in cells treated with AP-1
siRNA, suggesting that AP-1 siRNA had no further effect on virion release when compared
with the reduction in cell-associated Gag, whereas AP-3 siRNA treatment reduced virion-asso-
ciated p27 by 67% (Fig 4D), suggesting a further effect on release above the effect on cellular
Gag levels. Again, treatment with AP-1 and AP-3 siRNAs together had an additive effect on
both cell-associated p57 and p27, and virion-associated p27. Together these results suggest that
AP-3 is required for the delivery or recycling of Gag and/or HIV-2 particles from intracellular
sites to the extracellular space, and that accumulation of particles at these intracellular sites
leads to their degradation.
AP-3 and clathrin co-localize strongly with HIV-2 Gag
Given the possibility that AP-3 may function in the trafficking of HIV-2 Gag between intracel-
lular compartments and the cell surface, we next looked at whether AP-3 co-localized with
HIV-1 or HIV-2 Gag. Fig 5A–5C shows that HIV-1 Gag and AP-3 do not co-localize
(Rr = 0.206) in HeLa cells whereas HIV-2 Gag and AP-3 co-localize strongly (Fig 5D–5F,
Rr = 0.736). Furthermore, the distribution of AP-3 was different in cells expressing HIV-2 Gag,
compared to untransfected cells, or those expressing HIV-1 Gag, as AP-3 appeared to be
recruited to HIV-2 Gag-containing compartments. We also found this to be the case in 293T
cells (data not shown). HIV-1 GagPol, HIV-2 Gag and SIVmac Gag have also been reported to
interact with clathrin [28, 29]. AP-1 and AP-2 function in a primarily clathrin-dependent man-
ner, while AP-3 has been reported to function both with clathrin and independently of it [30].
We therefore also looked at whether clathrin co-localized with HIV-1 or HIV-2 Gag. Fig 5G–
5I shows that HIV-1 Gag and clathrin co-localize moderately (Rr = 0.435) in HeLa cells and
HIV-2 Gag and clathrin co-localize strongly, both at the plasma membrane and within the
cytoplasm (Rr = 0.671). Again, we saw the same result in 293T cells (data not shown). These
results suggest that AP-3 and clathrin may be involved in the trafficking of HIV-2 Gag to/from
intracellular compartments.
A novel adaptor protein complex, AP-5, is involved in HIV-2 Gag trafficking
While carrying out this study, a new adaptor protein complex was discovered, namely AP-5
[20]. Interestingly, the UniProt entry for the mu5 subunit includes a reference to “putative
HIV-2 Gag Trafficking
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Fig 5. HIV-2 Gag co-localizes strongly with AP-3 and clathrin.Confocal immunofluorescence microscopy was carried
out on HeLa cells transfected with HIV-1 (A-C, G-I) or HIV-2 (D-F, J-L) proviral plasmids. Gag is shown in red, AP-3 (B, C, E,
F) or clathrin (H, I, K, L) are shown in green and DAPI is shown in blue. The overlay of the three channels is shown in the
right hand image of each panel. Scale bars are shown in the bottom right hand corner of the overlay images. Mean Gag/AP-
3 or Gag/clathrin co-localization (Pearson’s correlation coefficient, Rr) is shown to the right of each panel.
doi:10.1371/journal.pone.0158941.g005
HIV-2 Gag Trafficking
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HIV-1 interacting protein” although we were unable to find any published data to support this.
We used an siRNA against AP-5μ previously reported [20] and tested its activity in HeLa cells
by RT-qPCR since no effective antibody was available, achieving 65% knock down of AP-5μ at
the mRNA level (Fig 6A). We then tested the effect of the AP-5 siRNA on HIV-1 and HIV-2
Gag localization in HeLa cells. Knock down of AP-5 had no effect on the distribution of HIV-1
Gag (Fig 6B), but it did reduce the percentage of cells with plasma membrane-associated HIV-
2 Gag, with a corresponding increase in cells with punctate Gag distribution. An increase in the
percentage of cells with diffuse distribution of Gag was also observed, although this change was
not found to be significant. (Fig 6C).
The relative levels of cell-associated and virion-associated HIV-1 and HIV-2 Gag were then
measured. AP-5 siRNA had no effect on the levels of cell- or virion-associated HIV-1 Gag (Fig
7A and 7B respectively), but it reduced cell-associated HIV-2 p57 and p27 (Fig 7C), and
virion-associated p27 (Fig 7D) by around 40%. This indicates that HIV-2 Gag is degraded in
the absence of AP-5 but processing and release are not further affected. Since AP-5 has been
shown to localize to late endosomal/lysosomal membranes [21], this suggests that AP-5 may be
involved in retrieval of HIV-2 Gag and/or particles from late endosomes/lysosomes.
Discussion
The data suggest that HIV-1 and HIV-2 Gag utilize different intracellular trafficking pathways
to their sites of particle assembly and their release at the cell surface. HIV-1 Gag assembles at
the plasma membrane in T cells, and in the cell lines used in this study; 293T and HeLa [8, 9].
As previously shown [16, 18], efficient HIV-1 particle release depends on the clathrin adaptor
proteins AP-1 and AP-3, implicating vesicular transport of Gag to the plasma membrane. Gag
binds to membranes via its myristylated N-terminal matrix (MA) domain [31], and therefore
may be transported on vesicular membranes. The effect of siRNA-mediated inhibition of AP-1
or AP-3 expression suggests similar volumes of HIV-1 Gag trafficking via these two pathways.
The increase in HIV-1 particle release when AP-2 is depleted (Fig 3, and previously shown
[17]) confirms that a proportion of HIV-1 Gag is internalized from the plasma membrane by
clathrin-mediated endocytosis. This work, and that of others [26] suggest that AP-1 and -3
may be involved in recycling HIV-1 Gag from endosomal compartments back to the cell
surface.
In contrast to HIV-1, we have shown that intracellular compartments are major sites of
HIV-2 Gag and/or particle accumulation in HeLa and 293T cells. Confocal immunofluores-
cence microscopy showed that HIV-2 Gag localized to CD63+/CD81+ puncta in 75% of cells.
Changes in subcellular distribution of HIV-2 Gag, in levels of cell-associated Gag and extracel-
lular virions, on siRNA-mediated depletion of AP-3 and -5, and strong co-localization of HIV-
2 Gag with AP-3, were all suggestive of a role for late endosomal compartments in HIV-2 Gag
trafficking. The data suggest that HIV-2 particles accumulate in late endosomal compartments
and that particle release then depends on AP-3 and -5 (and to a much lesser extent AP-1)
mediated recycling of late endosomal contents to the cell surface. If either of these adaptor pro-
teins are depleted, a greater proportion of Gag undergoes lysosomal degradation. However,
there are at least two possible interpretations of the route HIV-2 Gag takes to these compart-
ments: 1) As HIV-2 Gag assembles at the plasma membrane, many of the assembling particles
are internalized into endosomes. If this is the case, internalization occurs on a much greater
scale than for HIV-1 and by a mechanism other than clathrin-mediated endocytosis, since
depletion of AP-2 had no effect on HIV-2 particle release. 2) HIV-2 Gag assembles at intracel-
lular membranes and buds into these compartments directly. Further work will be required to
test these alternative, although not mutually exclusive, hypotheses.
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Fig 6. siRNA-mediated knockdown of AP-5 reduces plasmamembrane localization and increases
punctate distribution of HIV-2 Gag. (A) HeLa cells were transfected with 25 nMAP-5 siRNA or negative control
siRNA (-ve), or mock transfected (none). Cells were harvested 42 hours post-transfection, from which RNAwas
isolated and RT-qPCR carried out to detect AP-5μmRNA. Quantification was determined relative to GAPDH
mRNA. (B, C) HeLa cells were co-transfected with HIV-1 (B) or HIV-2 (C) proviral plasmids and no siRNA (none),
siRNA against AP-5μ or a negative control siRNA (-ve). Quantification of the effect of siRNAs on Gag
distribution, as determined by confocal immunofluorescence microscopy, is shown graphically. For each siRNA
treatment, at least 200 cells were assessed from three independent experiments. Cells were scored as having
predominantly plasma membrane (PM), punctate intracellular (punctate), or diffuse cytoplasmic (diffuse)
distribution of Gag. Representative confocal images are shown to the right, in which Gag is shown in red.
doi:10.1371/journal.pone.0158941.g006
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Fig 7. siRNA-mediated knockdown of AP-5 affects HIV-2 but not HIV-1 Gag.HeLa cells were co-
transfected with HIV-1 (A, B) or HIV-2 (C, D) proviral plasmids and no siRNA (none), siRNA against AP-5μ or
a negative control siRNA (-ve). 42 hours post-transfection, cell lysates and viral supernatants were
harvested. Cell-associated (A, C) and virion-associated (B, D) HIV-1 p55 (full length Gag), p41 (MA-CA) and
p24 (CA), and HIV-2 p57 (full length Gag) and p27 (CA) were detected by western blotting (representative
blots shown to the right) and quantified using densitometry. Error bars represent the standard error of the
mean from three independent experiments and significant changes from no siRNA treatment are shown with
an asterisk (p < 0.05).
doi:10.1371/journal.pone.0158941.g007
HIV-2 Gag Trafficking
PLOS ONE | DOI:10.1371/journal.pone.0158941 July 8, 2016 13 / 16
Previous work has shown mechanistic differences between HIV-1 and -2 Gag in their mem-
brane-binding, multimerization, and RNA-binding activities, which all affect particle assembly
[32–34]. While recombinant HIV-2 Gag was shown to bind to the plasma membrane in yeast
spheroplasts, it dissociated from the membrane more easily than HIV-1 Gag and did not form
higher order multimers, resulting in a lack of virus-like particle production. However, these dif-
ferences were not observed in human cell lines [32]. Structural studies of HIV-2 MA showed
that the N-terminal myristate group, which is required for efficient membrane binding of Gag,
is more tightly sequestered in its hydrophobic pocket in HIV-2 MA than HIV-1 MA, and does
not easily switch to an exposed conformation, even on binding to PI(4,5)P2, the plasma mem-
brane phosphoinositide that favours HIV-1 myristate exposure and Gag membrane binding
[33]. Despite this, electron microscopy of HeLa cells transfected with HIV-2 proviral plasmid
showed numerous extracellular viral particles in the vicinity plasma membrane, showing that
viral particles could be assembled and released [33]. Recently, the RNA-binding and nucleic
acid chaperone activities of HIV-1 and -2 Gag were shown to differ, with MA contributing to
the chaperone activity of HIV-2 but not HIV-1 Gag [34]. These studies suggest that HIV-1 and
HIV-2 have evolved slightly different strategies for particle assembly and release.
Interestingly, the newly identified adaptor protein complex AP-5, which localizes to late
endosomal/lysosomal membranes [21], was found to be required for HIV-2, but not HIV-1,
particle production. Of note, it is estimated that there are around 30-fold less copies of the AP-
5 complex than either the AP-1 or AP-3 complex in HeLa cells [35]. The fact that siRNA
knockdown of AP-5 had a significant effect on the level of cellular HIV-2 Gag despite the con-
tinued presence of a large excess of AP-1 and AP-3 suggests that it plays an important role in
HIV-2 particle production.
The different pathways discussed all likely depend on the microtubule-dependent move-
ment of vesicles or endosomal compartments. Movement along microtubules toward the cell
periphery is usually driven by the plus-directed kinesin motor proteins [36]. HIV-1 Gag traf-
ficking has been reported to require the kinesin KIF4 in COS-1 cells [37], and KIF3A in pri-
mary macrophages, where it was required for release of HIV-1 particles from VCCs [38]. AP-3
has been reported to interact directly with KIF3A [39], making this motor protein a good can-
didate for further studies on HIV-2 particle release.
In conclusion, the data presented in this study highlight that, in contrast to HIV-1, HIV-2
Gag accumulates in intracellular compartments in non-macrophage cells. HIV-2 particle pro-
duction is dependent on the adaptor proteins AP-3 and AP-5 for delivery of particles from
intracellular compartments to the cell surface, and their depletion leads to viral particle degra-
dation. The implications of this research are that mechanistic differences between HIV-1 and
HIV-2 in the trafficking, assembly and release of viral particles could contribute to the lower
viral load observed during HIV-2 infection.
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